Pfizer defended its once-monthly obesity GLP-1 strategy with new mid-stage data for berobenatide after patients transitioned from weekly to monthly dosing. The results, presented at the American Diabetes Association meeting, showed continued weight loss through 28 weeks without an apparent plateau for those maintained on treatment, adding momentum for a dosing schedule that could compete with weekly injectables.